Merck to Present New Data Highlighting Durable Effects of MAVENCLAD ® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
17.9.2025 15:00:00 EEST | Business Wire | Press release
Not intended for UK-, US- or Canada-based media
Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona.
“As the only high-efficacy short-course oral treatment, MAVENCLAD has demonstrated sustained benefits across a variety of outcomes—extending beyond relapses and MRI—without requiring continuous immunosuppression,” said Alex Kulla, Senior Vice President & Global Head of the Neurology & Immunology Medical Unit for the Healthcare business of Merck. “With over two decades of clinical experience and substantial real-world data, MAVENCLAD has been utilized to treat more than 130,000 individuals, amounting to over 360,000 patient-years of exposure. The comprehensive data presented at ECTRIMS 2025 reinforces its role in delivering durable, effective care for individuals with RMS—supporting them from early diagnosis through later stages of life.”
Key MAVENCLAD data:
-
An integrated analysis of four-year data from CLARIFY-MS (n=482) and MAGNIFY-MS (n=270), including their extension studies, showed low rates of disability accumulation and progression independent of relapse activity (PIRA) in patients treated with MAVENCLAD, especially those who initiated treatment in the early stages of their disease.
- At Year 4, 83.4% of patients were free from confirmed disability progression (CDP) and 89.2% were free from PIRA.
- 15.4% experienced confirmed disability improvement (CDI).
- Patients aged ≤40 experienced lower rates of PIRA compared to those over 40 (7.6% vs. 15.4%, respectively).
- The analysis demonstrated that MAVENCLAD provided durable efficacy after short-course treatment, with long-term control over both inflammatory and non-inflammatory components of MS-related disability.
-
Data from MAGNIFY-MS showed MAVENCLAD reduced serum and cerebrospinal fluid (CSF) biomarkers of neuroinflammation, suggesting a broader central nervous system (CNS) benefit.
- At Year 2, reductions were observed in key biomarkers, including serum glial fibrillary acidic protein (GFAP), immunoglobulin G (IgG) index, and C-X-C motif chemokine ligand 13 (CXCL-13) levels.
-
Brain imaging data from MAGNIFY-MS indicated that the brain atrophy rate in MAVENCLAD-treated patients was comparable to that observed in the healthy population, reinforcing the importance of brain volume (BV) preservation as a therapeutic goal in MS.
- From Years 2 to 4, annualized percent BV change remained below 0.4%, across all subgroups.
- Patients with low brain atrophy rates at Year 4 had markedly lower annualized relapse rate (ARR) (0.04 ±0.12 vs. 0.16 ±0.26) and less clinical deterioration compared to those with annualized percentage BV change exceeding -0.4%.
Additional MAVENCLAD presentations:
- Poster Presentation Title: Treatment Continuation With Cladribine Tablets Beyond Year 4: Analysis of Longitudinal Prescription Data From Germany
- Lead Author: David Kormann, Real World Data Analytics, IQVIA Commercial GmbH & Co. OHG, Frankfurt, Germany
- Poster Presentation Title: Treatment continuation with cladribine tablets (CladT) beyond year 4– second interim analysis of the CLIP-5 study
- Lead Author: Catharina Korsukewitz, University Hospital Muenster, Muenster, Germany
- Poster Presentation Title: Incidence Rate of Malignancies in People with Multiple Sclerosis Newly Initiating Cladribine Tablets or Fingolimod: Second Interim Results from CLARION
- Lead Author: Anna Glaser, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- Poster Presentation Title: Clinical Outcomes of Cladribine Tablets in Aging (≥50 years) Patients with Relapsing Multiple Sclerosis in a Real-World Setting: Insights From the ‘Aging’ Study
- Lead Author: Joshua Katz, Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA, United States
Below is the full list of MAVENCLAD abstracts accepted for presentation at ECTRIMS 2025:
The Effect of Cladribine Tablets on Brain Volume over 4 Years in the MAGNIFY-MS Extension Study | Barkhof F, Schmierer K, Vermersch P, et al. | Poster: P687 Session: Poster Session 2 Date: September 25, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Barkhof F |
Impact of Cladribine Tablets on GFAP Levels and Intrathecal Biomarkers in RMS: Results from the MAGNIFY-MS Study | Wiendl H, Derfuss T, Sponton L, et al. | Poster: P1694 Session: ePoster Date: September 24-26, 2025 Presenter: Wiendl H |
Long-Term Effect of Cladribine Tablets on Disability Progression and Improvement: Insights from Pooled Analyses of CLARIFY-MS and MAGNIFY-MS Studies | Vermersch P, Wiendl H, Leocani L, et al. | Poster: P335 Session: Poster Session 1 Date: September 24, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Vermersch P |
Cladribine Tablets Show Low 4-Year PIRA Rates in MS: Insights from Pooled Analyses of CLARIFY-MS and MAGNIFY-MS Studies | Montalban X, De Stefano N, Hodgkinson S, et al. | Poster:P1707 Session: ePoster Date: September 24-26, 2025 Presenter: Montalban X |
Comparing Changes in Brain Tissue Damage Between the Two-year Active Dosing Treatment Period and the Following Two Years Extension Period in Cladribine-treated MS Patients Stratified by MRI Phenotypes | De Stefano N, Sforazzini F, Luchetti L, et al. | Poster: P208 Session: Poster Session 1 Date: September 24, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: De Stefano N |
Cladribine Tablets-treated Multiple Sclerosis Patients Show Different Spatio-temporal Patterns of Acute, Chronic and Resolving Brain Inflammatory Activity | Gentile G, Smyk A, Ben-Amor A-F, et al. | Poster: P1450 Session: ePoster Date: September 24-26, 2025 Presenter: Gentile G |
Using Deep Learning on Baseline MRI Data for Highly Accurate Prediction of Cladribine Tablets-treated MS Patients who Improve Physical and Cognitive Disability in 4 Years | Battaglini M, Sforazzini F, Luchetti L, et al. | Poster: P672 Session: Poster Session 2 Date: September 25, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Battaglini M |
Incidence Rate of Malignancies in People with Multiple Sclerosis Newly Initiating Cladribine Tablets or Fingolimod: Second Interim Results from CLARION | Glaser A, Ziemssen T, Butzkueven H, et al. | Poster: P856 Session: Poster Session 2 Date: September 25, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Glaser A |
Real-world Experience with Cladribine (Mavenclad) in the MSBase Registry 2025 | Spelman T, van der Walt A, Ozakbas S, et al. | Poster: P875 Session: Poster Session 2 Date: September 25, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Butzkueven H |
Treatment Continuation With Cladribine Tablets Beyond Year 4: Analysis of Longitudinal Prescription Data From Germany | Kormann D, Parekh M, von der Maßen K, et al. | Poster: P1773 Session: ePoster Date: September 24-26, 2025 Presenter: Kormann D |
Real-world Experience with Cladribine Tablets in Older Age Groups in the MSBase Registry | Spelman T, van der Walt A, Havrdova E, et al. | Poster: P1985 Session: ePoster Date: September 24-26, 2025 Presenter: Butzkueven H |
Cladribine Tablets Reduce Pathological Brain Ageing Gap in MS Patients | Leoncini M, Battaglini M, Sforazzini F, et al. | Poster: P432 Session: Poster Session 1 Date: September 24, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Leoncini M |
Clinical Outcomes of Cladribine Tablets in Aging (≥50 years) Patients with Relapsing Multiple Sclerosis in a Real-World Setting: Insights From the ‘Aging’ Study | Katz J, Hughes B, Gutierrez A, et al. | Poster: P332 Session: Poster Session 1 Date: September 24, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Katz J |
Relationship Between CSF Cellular Populations and MRI Biomarkers of MS Disease Severity: Insights from the CLOCK-MS Study | Samara A, Judge B, Salter A, et al. | Poster: P1471 Session: ePoster Date: September 24-26, 2025 Presenter: Brier MR |
Three-Year Effectiveness and Safety Data for Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Transitioning from Natalizumab (CLADRINA Study) | Sguigna P, Okai A, Kaplan J, et al. | Poster: P1947 Session: ePoster Date: September 24-26, 2025 Presenter: Sguigna P |
Treatment Continuation with Cladribine Tablets (CladT) Beyond Year 4– Second Interim Analysis of the CLIP-5 Study | Korsukewitz C, Richter N, Klehmet J, et al. | Poster: P1803 Session: ePoster Date: September 24-26, 2025 Presenter: Korsukewitz C |
Long-term Effects of Treatment with Cladribine Tablets on Cognition and Treatment Satisfaction in People with Relapsing Multiple Sclerosis: 4‑year Results from the Noninterventional CLADQoL Study | Penner I-K, Chudecka A, Refik P, et al. | Poster: P1820 Session: ePoster Date: September 24-26, 2025 Presenter: Penner I-K |
48 Month Follow-up of Maven4: a Phase IV Non-interventional, Prospective, Spanish Multicenter Study to Assess the Long Term Effectiveness of Cladribine Tablets in Real-world Clinical Practice | Aladro-Benito Y, Costa-Frossard L, Sánchez Magro MI, et al. | Poster: P346 Session: Poster Session 1 Date: September 24, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Aladro-Benito Y |
Design and Baseline Characteristics of the Real-world MAVENAGE Study in Relapsing MS Patients Older and Younger Than 50 Years Treated with Cladribine Tablets | Meca-Lallana JE, Eichau S, Oreja-Guevara C, Meca V, et al. | Poster: P1649 Session: ePoster Date: September 24-26, 2025 Presenter: Meca-Lallana JE |
Retrospective Analysis of Multiple Sclerosis Patients Who Initiated Oral Cladribine 5-8 Years Ago – Data from a German Cladribine Cohort | Woitschach L, Cepek L, Kowarik M, et al. | Poster: P357 Session: Poster Session 1 Date: September 24, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Ernst M |
Clinical Effectiveness of Cladribine Tablets for PwMS Switching from Natalizumab, AntiCD20 Treatment or “Other”; Data from the Swedish Post-market Surveillance Study “Immunomodulation and Multiple Sclerosis Epidemiology 10” (IMSE 10) | Forsberg L, Larsson V, Hillert J, et al. | Poster: P1762 Session: ePoster Date: September 24-26, 2025 Presenter: Forsberg L |
Clinical Effectiveness and Safety of Cladribine Tablets for PwMS Treated at Least 36 Months in the Swedish Post-market Surveillance Study “Immunomodulation and Multiple Sclerosis Epidemiology 10” (IMSE 10) | Forsberg L, Larsson V, Hillert J, et al. | Poster: P344 Session: Poster Session 1 Date: September 24, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Forsberg L |
Clinical Effectiveness of Cladribine Tablets for Patients Below or Above 50 Years of Age at Treatment Start in the Swedish Post-market Surveillance Study "Immunomodulation and Multiple Sclerosis Epidemiology 10" (IMSE 10) | Larsson V, Forsberg L, Hillert J, et al. | Poster: P861 Session: Poster Session 2 Date: September 25, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Larsson V |
CLADCOMS - CLADribine Tablets Long-term Control of MS – a Post-Marketing Investigator Driven Study | Larsson V, Forsberg L, Nilsson P, et al. | Poster: P865 Session: Poster Session 2 Date: September 25, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Larsson V |
Clinical Effectiveness of Cladribine Tablets for Patients with Few vs Many Treatments Prior CladT Initiation in the CLADCOMS Study -CLADribine Tablets Long-term Control Of MS – a Post-marketing Investigator Driven Study | Larsson V, Forsberg L, Nilsson P, et al. | Poster: P1804 Session: ePoster Date: September 24-26, 2025 Presenter: Larsson V |
Recurrent Effects on the Clonal Composition of Peripheral B Cells in MS Patients During the Second Year of Cladribine Treatment | Tieck MP, Vasilenko N, Stadelmaier J, et al. | Poster: P813 Session: Poster Session 2 Date: September 25, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Tieck MP |
Preliminary Data of Paramagnetic Rim Lesion Dynamic at 7 Tesla Magnetic Resonance Imaging in Cladribine Tablets-Treated People with Multiple Sclerosis | Dal-Bianco A, Hametner S, Grabner G, et al. | Poster: P216 Session: Poster Session 1 Date: September 24, 2025 Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT Presenter: Dal-Bianco A |
Baseline and Early Safety Data Following Full Recruitment of ChariotMS, the First DMT trial for People with Advanced MS (EDSS 6.5-8.5) | Schmierer K, Mattoscio M, De Angelis F, et al. | Poster: P1633 Session: ePoster Date: September 24-26, 2025 Presenter: Schmierer K |
Breaking Inflammatory Cycles: Cladribine Targets Pathogenic B Cell Subsets in Multiple Sclerosis | Pirronello M, Picozza M, Corbisiero S, et al. | Poster: P1374 Session: ePoster Date: September 24-26, 2025 Presenter: Battistini L |
Circulating MicroRNAs as Potential Biomarkers for Treatment Response in Cladribine-Treated Multiple Sclerosis Patients | Vigiser I, Zeevi Y, Piura Y, Kolb H, Golan M, Karni A, Regev K | Poster: P762 Session: ePoster Date: September 24-26, 2025 Presenter: Vigiser I |
Integrin β1 Demarks Circulating Precursors of Brain-residing Antibody-secreting Cells in People with MS | Kuiper K, Bogers L, Rip J, et al. | Oral presentation: O123 Session: Scientific Session 14: Antibody-mediated pathology Date: September 26, 2025 Time: 12:26-12:33 am PDT/03:26-03:33 am EDT Presenter: Smolders J |
Early Lymphocyte Reduction as a Potential Marker of Cladribine Efficacy | Celius E, et al. | Poster: P2028 Session: ePoster Date: September 24-26, 2025 Presenter: Celius E |
About MAVENCLAD®
MAVENCLAD, approved by the U.S. Food and Drug Administration (FDA) on March 29, 2019, is the first and only short-course oral therapy for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS). Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of multiple sclerosis (MS), and MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS). Patients should follow healthcare provider instructions including cancer screening, contraception, and blood tests. The approved dose of MAVENCLAD is 3.5 mg per kg body weight over two years, administered as one treatment course of 1.75 mg per kg per year, each consisting of two treatment weeks. The mechanism by which cladribine exerts its therapeutic effects in patients with multiple sclerosis has not been fully elucidated but is thought to involve cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes. MAVENCLAD causes a dose-dependent reduction in lymphocyte counts followed by recovery.
Because cladribine is cytotoxic, special handling and disposal instructions should be followed.
More than 130,000 patients have been treated with MAVENCLAD since its launch in 2019. MAVENCLAD has been approved in over 80 countries, including the European Union (EU), Canada, Australia and Switzerland, for various relapsing MS indications. Visit www.MAVENCLAD.com for more information.
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.9 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company’s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and generalized myasthenia gravis (gMG).
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck generated sales of € 21.2 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250917717443/en/
Contacts
Media Relations
Flavia.felix@emdserono.com
Phone: +1 781 427 1892
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FinXP Partners with Thredd to Strengthen Multi-Region Card Issuing Capabilities9.9.2026 10:00:00 EEST | Press release
FinXP, a European payment infrastructure provider, has partnered with Thredd, the AI-first issuer processing platform, to strengthen FinXP’s card issuing capabilities and support the next phase of its embedded finance offering. The partnership with Thredd will enable FinXP to enhance its debit card programmes with a modern issuer-processing stack, supporting tokenisation, provisioning, risk and fraud prevention, card controls, and automated back-office operations. FinXP will retain control of its own ledger and programme strategy, while Thredd will provide the programme infrastructure needed to support secure, scalable and flexible card issuing across multiple regions. FinXP has been issuing cards for five years and already supports businesses with accounts, payments, collections, payouts, card issuing and embedded finance solutions. The partnership with Thredd marks a further step in FinXP’s strategy to provide scalable, multi-region payment infrastructure to fintechs, platforms and b
HSCALE Secures Landmark Strategic Deal With Major US Cloud Provider for Hyperscale Data Centre Campus in Spain9.9.2026 10:00:00 EEST | Press release
HSCALE, the pan-European hyperscale data centre platform, announced today a major strategic deal with a significant global cloud provider to deliver large-scale, high-performance digital infrastructure in a strategic metropolitan area within the Iberian Peninsula. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909242953/en/ HSCALE's CCO Paul Berry-Selwood The agreement is a defining milestone for HSCALE and anchors the development of a next-generation campus designed for the demanding requirements of hyperscale cloud and artificial intelligence workloads. In a deal worth more than US$1billion, the development is currently one of the largest data centres currently under construction in Spain. This deal provides a framework for both parties to progress further infrastructure opportunities across EMEA. Located in one of Europe's largest and most strategically important metropolitan markets, the project will add critical capa
Fighting Fire with Fire: Mobileum and Apate Shut Down Scam Operations From the Inside Out9.9.2026 10:00:00 EEST | Press release
Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, and Apate.ai (“Apate”) have announced a partnership that equips communications service providers (CSPs) with advanced AI-powered fraud prevention capabilities designed to detect, disrupt, and investigate scam call operations. According to the Global Anti-Scam Alliance, scammers stole an estimated $442 billion in 2025, with phone calls, text messages and emails being the top three communication channels used by scammers. Through the integration of Mobileum’s Active Intelligence Platform with Apate's conversational AI agents, CSPs can now move beyond traditional call blocking and take a more proactive role in disrupting scam activity. Rather than simply preventing suspicious calls, messages and other communications from reaching customers, the solution engages fraudsters directly, collecting valuable intelligence that helps identify tactics, uncover networks, expose the artifacts they use (bank acco
KONGSBERG Selects Echodyne MESA Radar for Counter-UAS Weapon Systems9.9.2026 09:00:00 EEST | Press release
Echodyne, the radar platform company, today announced that KONGSBERG has selected Echodyne's MESA® radar platform for a range of air and surface applications. Among the first use cases, KONGSBERG has integrated MESA radar into the PROTECTOR RS4 and PROTECTOR RS6 remote weapon stations (RWS), adding the precision radar data needed to turn the world's most widely deployed RWS family into a highly effective counter-unmanned aircraft system (C-UAS) effector. The selection pairs KONGSBERG's proven weapon-station architecture and Collaborative Fire Control capabilities with Echodyne's compact, solid-state radar. The result is a scalable approach for adding high-fidelity detection, tracking and targeting data to static, crewed and uncrewed platforms without the size, weight and power demands traditionally associated with high-performance electronically scanned array radar. "KONGSBERG has set the standard for remote weapon systems through decades of field experience, disciplined engineering an
With More Than 2,000 Visitors, ATARASHII GAKKO! and Morimoto of Tontsukatan Lead the Opening-Day Countdown9.9.2026 04:07:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907649202/en/ With More Than 2,000 Visitors, ATARASHII GAKKO! and Morimoto of Tontsukatan Lead the Opening-Day Countdown We are pleased to announce that two new projection mapping works featuring “OTONABLUE,” the signature song of ATARASHII GAKKO!, a four-member dance and vocal group active on the global stage, and their latest song, “TTTTOKYO,” began screening on Sunday, August 23. On opening day, a special event was held featuring ATARASHII GAKKO! and Morimoto of Tontsukatan as guests. Together with more than 2,000 visitors gathered at the venue, they led a countdown to the very first screen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom